Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336


Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.

Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E.

J Virol. 2004 Apr;78(8):4108-19.


EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.

Le Clorennec C, Youlyouz-Marfak I, Adriaenssens E, Coll J, Bornkamm GW, Feuillard J.

Blood. 2006 Mar 1;107(5):2070-8. Epub 2005 Nov 29.


c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08. Epub 2009 Mar 4.


Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.

De Leo A, Arena G, Stecca C, Raciti M, Mattia E.

Mol Cancer Res. 2011 Oct;9(10):1346-55. doi: 10.1158/1541-7786.MCR-11-0145. Epub 2011 Aug 19.


An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.

Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, Longnecker R, Kieff E.

J Virol. 1999 Dec;73(12):10525-30.


Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.

Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS.

Mol Cell Biol. 2004 Jun;24(12):5223-34.


Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Lai KY, Chou YC, Lin JH, Liu Y, Lin KM, Doong SL, Chen MR, Yeh TH, Lin SJ, Tsai CH.

J Virol. 2015 Jun;89(11):5968-80. doi: 10.1128/JVI.00168-15. Epub 2015 Mar 25.


Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.

Rowe M, Raithatha S, Shannon-Lowe C.

J Virol. 2014 Oct;88(20):12065-76. doi: 10.1128/JVI.01431-14. Epub 2014 Aug 13.


Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Le Clorennec C, Ouk TS, Youlyouz-Marfak I, Panteix S, Martin CC, Rastelli J, Adriaenssens E, Zimber-Strobl U, Coll J, Feuillard J, Jayat-Vignoles C.

J Virol. 2008 Jul;82(13):6721-33. doi: 10.1128/JVI.02250-07. Epub 2008 Apr 30.


Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways.

Goormachtigh G, Ouk TS, Mougel A, Tranchand-Bunel D, Masy E, Le Clorennec C, Feuillard J, Bornkamm GW, Auriault C, Manet E, Fafeur V, Adriaenssens E, Coll J.

J Virol. 2006 Aug;80(15):7382-93.


Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.

D'Souza BN, Edelstein LC, Pegman PM, Smith SM, Loughran ST, Clarke A, Mehl A, Rowe M, Gélinas C, Walls D.

J Virol. 2004 Feb;78(4):1800-16.


Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.

Martin HJ, Lee JM, Walls D, Hayward SD.

J Virol. 2007 Sep;81(18):9748-58. Epub 2007 Jul 3.


Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA.

J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57.


Supplemental Content

Support Center